{"entity":{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of VS-7375 in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., now recruiting.","summary":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07659782 by Verastem, Inc., with 105 participants planned, started 2026-07-22 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07659782","url":"https://clinicaltrials.gov/study/NCT07659782"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vs-7375"],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07659782","phase":"2","setting":"A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","sponsor":"Verastem, Inc.","enrolled":105,"outcomes":[]},"route":"/trials/nct07659782/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}]}}